Anatara Lifesciences : Change of Director's Interest Notice

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anatara Lifesciences Limited
ABN	41 145 239 872

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Brookes
Date of last notice	4 December 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct & Indirect
Nature of indirect interest	Indirect - David & Elisabeth Brookes atf Dr
(including registered holder)	DL Brookes Personal Superfund
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change	9 December 2021
No. of securities held prior to change	Indirect - David & Elisabeth Brookes atf Dr
	DL Brookes Personal Superfund 300,000
	Ordinary Shares &
	65,658 Options with an exercise price of
	$0.2476 and expire on 3 December 2022
Class	Options
Number acquired	Direct:
	900,000 at $0.225 ea; vesting 450,000 16
	November 2022 & 450,000 16 November
	2023; expire 14 November 2025
Number disposed	Nil
Value/Consideration	Nil
Note: If consideration is non-cash, provide details and estimated
valuation

• See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1

For personal use only

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	Direct:
	900,000 at $0.225 ea; vesting 450,000 16
	November 2022 & 450,000 16 November
	2023; expire 14 November 2025
	Indirect - David & Elisabeth Brookes atf Dr
	DL Brookes Personal Superfund 300,000
	Ordinary Shares &
	65,658 Options with	an exercise price	of
	$0.2476 and expire on 3 December 2022
Nature of change
Example: on-market trade, off-market trade, exercise of options,	The issued Options	were approved	by
issue of securities under dividend reinvestment plan, participation in
Shareholders at the Annual General Meeting
buy-back
	held on 16 November 2021

Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract

Nil

Nature of interest

Name of registered holder (if issued securities)

Date of change

No. and class of securities to which interest related prior to change

Note: Details are only required for a contract in relation to which the interest has changed

Interest acquired

Interest disposed

Value/Consideration

Note: If consideration is non-cash, provide details and an estimated valuation

Interest after change

Part 3 - +Closed period

Were the interests in the securities or contracts detailed N/A above traded during a +closed period where prior written clearance was required?

+ See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

For personal use only

Appendix 3Y

Change of Director's Interest Notice

If so, was prior written clearance provided to allow the trade	N/A
to proceed during this period?
If prior written clearance was provided, on what date was this	N/A
provided?

• See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Anatara Lifesciences Limited
ABN	41 145 239 872

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Sue MacLeman
Date of last notice	13 September 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest	N/A
(including registered holder)
Note: Provide details of the circumstances giving rise to the relevant
interest.
Date of change	9 December 2021
No. of securities held prior to change	Indirect - Dalroar Pty Ltd (MacLeman
	Investment Trust) 78,069 Ordinary Shares &
	122,548 Options with an exercise price of
	$0.2476 and expire on 3 December 2022
Class	Options
Number acquired	Indirect - Dalroar Pty Ltd (MacLeman
	Investment Trust)
	450,000 Options at $0.225 ea; vesting
	225,000 16 November 2022 & 225,000 16
	November 2023; expire 14 November 2025
Number disposed	Nil
Value/Consideration	Nil
Note: If consideration is non-cash, provide details and estimated
valuation

• See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1

For personal use only

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	Indirect - Dalroar Pty Ltd (MacLeman
	Investment Trust) 78,069 Ordinary Shares;
	122,548 Options with an exercise price of
	$0.2476 and expire on 3 December 2022
	& 450,000 Options at $0.225 ea; vesting
	225,000 16 November 2022 & 225,000 16
	November 2023; expire 14 November 2025
Nature of change
Example: on-market trade, off-market trade, exercise of options,	The issued Options were approved by
issue of securities under dividend reinvestment plan, participation in
Shareholders at the Annual General Meeting
buy-back
	held on 16 November 2021

Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Nil
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change

Part 3 - +Closed period

Were the interests in the securities or contracts detailed N/A above traded during a +closed period where prior written clearance was required?

If so, was prior written clearance provided to allow the trade N/A to proceed during this period?

+ See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011